These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35435090)

  • 21. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term hydroxyurea therapy in beta-thalassaemia patients.
    de Paula EV; Lima CS; Arruda VR; Alberto FL; Saad ST; Costa FF
    Eur J Haematol; 2003 Mar; 70(3):151-5. PubMed ID: 12605659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.
    Kosaryan M; Zafari M; Alipur A; Hedayatizadeh-Omran A
    Hemoglobin; 2014; 38(4):262-71. PubMed ID: 25023087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
    Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
    Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
    Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
    Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
    Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
    Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
    [No Abstract]   [Full Text] [Related]  

  • 27. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
    Karimi M; Haghpanah S; Farhadi A; Yavarian M
    Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
    Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
    J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
    Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
    Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
    Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
    Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports.
    Karimi M; Cohan N; Pishdad P
    Hematology; 2015 Jan; 20(1):53-7. PubMed ID: 24717020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.
    Karimi M; Cohan N; Mousavizadeh K; Falahi MJ; Haghpanah S
    Pediatr Hematol Oncol; 2010 Apr; 27(3):205-11. PubMed ID: 20367264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
    Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ
    Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.